BioMarin Pharmaceutical Inc. (BMRN)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.
Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase.
In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria.
The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally.
BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd.
The company was incorporated in 1996 and is headquartered in San Rafael, California.
Country | United States |
IPO Date | Jul 26, 1999 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 3,401 |
CEO | Alexander Hardy |
Contact Details
Address: 770 Lindaro Street San Rafael, California United States | |
Website | https://www.biomarin.com |
Stock Details
Ticker Symbol | BMRN |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001048477 |
CUSIP Number | 09061G101 |
ISIN Number | US09061G1013 |
Employer ID | 68-0397820 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Alexander Hardy | President, Chief Executive Officer & Director |
Amy Wireman | Executive Vice President & Chief People Officer |
Brian R. Mueller CPA | Chief Financial Officer & Executive Vice President |
Dr. C. Greg Guyer Ph.D. | Executive Vice President & Chief Technology Officer |
George Eric Davis J.D. | Executive Vice President, Chief Legal Officer, General Counsel & Secretary |
Humaira Serajuddin | Senior Vice President & Chief Marketing Officer |
Dr. Henry J. Fuchs M.D., Ph.D. | Advisor |
Dr. Kevin Eggan Ph.D. | Chief Scientific Officer & Senior Vice President of Research and Early Development |
Erin Burkhart | Group Vice President & Chief Accounting Officer |
Traci McCarty | Group Vice President of Investor Relations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 03, 2024 | 4 | Filing |
Nov 14, 2024 | 4 | Filing |
Oct 31, 2024 | 10-Q | Quarterly Report |
Oct 29, 2024 | 8-K | Current Report |
Oct 01, 2024 | 4 | Filing |
Oct 01, 2024 | 3 | Filing |
Sep 30, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
Sep 24, 2024 | 8-K | Current Report |
Sep 17, 2024 | 4 | Filing |
Sep 04, 2024 | 8-K | Current Report |